2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis. Issue 1 (2nd January 2019)

• Record Type: Journal Article
• Authors: Harigai, Masayoshi; Nagasaka, Kenji; Amano, Koichi; Bando, Masashi; Dobashi, Hiroaki; Kawakami, Tamihiro; Kishibe, Kan; Murakawa, Yohko; Usui, Joichi; Wada, Takashi; Tanaka, Eiichi; Nango, Eishu; Nakayama, Takeo; Tsutsumino, Michi; Yamagata, Kunihiro; Homma, Sakae; Arimua, Yoshihiro
• Is Part Of: Modern rheumatology. Volume 29:Issue 1(2019)
• Page Start: 20
• Page End: 30
• Publication Date: 2019-01-02
• Subjects: ANCA-associated vasculitis -- clinical practice guideline -- GRADE system -- microscopic polyangiitis -- granulomatosis with polyangiitis; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/14397595.2018.1500437
• Languages: English
• ISSNs: 1439-7595

Abstract

Abstract: Objective: The Japan Research Committee for Intractable Vasculitis has fully revised the clinical practice guidelines (CPG) for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) to improve and standardize the medical treatment of the disease in Japan. Methods: The previous CPG was published in a classical review style in Japanese in 2011 and 2014. We adopted the Grading of Recommendations Assessment, Development and Evaluation system for this revision, and various stakeholders, including patients, participated in it. The expected users of this CPG are AAV patients in Japan and their families and healthcare professionals, including both AAV specialists and non-specialists. We set clinical questions concerning the three important clinical topics of remission induction therapy, plasma exchange, remission maintenance therapy, and developed eight recommendation statements. Results: For remission induction therapy for newly developed AAV, we weakly recommend glucocorticoid (GC) plus intravenous cyclophosphamide pulse (IVCY) or oral cyclophosphamide (POCY) rather than GC alone, and IVCY rather than POCY. We also weakly recommend CY rather than rituximab. In the case of AAV with severe renal impairment, we weakly recommend plasma exchange as a conjunction therapy. We weakly recommend azathioprine for remission maintenance therapy. Conclusion: The revised CPG has demonstrated evidence-based treatment recommendations for AAV.